帕博利珠单抗后线治疗转移性黑色素瘤九年生存者特征与生活质量
本研究基于德国扩大可及项目(EAP)真实世界队列,评估伊匹木单抗进展后(必要时BRAF/MEK抑制剂后)接受帕博利珠单抗治疗的IV期黑色素瘤患者长期结局。325例中55例(17%)在中位随访9.1年后存活,缓解率89%(完全缓解69%),71%发生免疫相关不良事件(irAE),35%有持续症状,但标准工具测量的生活质量总体良好。
要点
- 后线帕博利珠单抗在真实世界经治黑色素瘤中可获得长期生存,17%存活近十年。
- 存活者缓解率89%、完全缓解69%,84%随访时无病。
- 71%发生irAE(27%为3/4级),35%有持续症状,主要为内分泌缺陷、白癜风和乏力。
核心结论
- 帕博利珠单抗在真实世界经治转移性黑色素瘤队列中诱导了长期生存。
- 尽管三分之一存活者有持续症状,近十年后多数存活者标准工具测量的生活质量良好。
研究设计与样本
- 真实世界队列研究,评估德国扩大可及项目(EAP)中开始帕博利珠单抗治疗的患者生存。
- 纳入≥10例患者的肿瘤中心,对存活者回顾性评估基线特征、最佳缓解和irAE,并横断面访谈持续症状和生活质量(WHO-5、EORTC QLQ-C30)。
主要发现
- 325例治疗患者中55例(17%)在中位随访9.1年后存活。
- 存活者治疗开始时中位年龄60岁,60%为男性,40% BRAF突变,66%为M1c/d期。
- 总缓解率89%,包括69%完全缓解;22例(40%)出现进展。
- 截至2024年5月,46例(84%)无病,7例(13%)疾病控制,2例(4%)进展。
- 39例(71%)发生irAE,其中15例(27%)为3/4级;19例(35%)报告持续症状,主要为内分泌缺陷、白癜风和乏力。
关键数值与推荐
- 中位WHO-5评分为76%,QLQ-C30总体健康均值为70.1。
- 有irAE史的存活者WHO-5生活质量(p=0.026)和QLQ-C30社会功能(p=0.046)显著更低。
- 21例<65岁存活者(38%)中,11例(20%)随访时在职。
临床怎么用
- 对经伊匹木单抗及必要时BRAF/MEK抑制剂进展的IV期黑色素瘤患者,帕博利珠单抗后线治疗可带来长期生存机会。
- 长期随访中需关注irAE史者的生活质量和社交功能,尤其内分泌缺陷、白癜风和乏力等持续症状。
局限性
- 真实世界回顾性设计,仅纳入≥10例患者的中心,可能存在选择偏倚。
- 存活者样本量较小(55例),横断面生活质量评估可能受幸存者偏倚影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Immune checkpoint blockers have improved survival in metastatic melanoma. Long-term quality of life (QoL) and sequelae from immune-related adverse events (irAE) are therefore of increasing importance. This study reports long-term outcomes from a real-world cohort of patients with stage IV melanoma treated with pembrolizumab after progression on ipilimumab and, if indicated, BRAF/MEK inhibition. METHODS: Survival of patients who started treatment with pembrolizumab within the German Expanded Access Program (EAP) were evaluated in Cancer centers that included ≥ 10 patients. For survivors, baseline characteristics, best response and irAEs were assessed retrospectively. In addition, in a cross-sectional approach patients were interviewed for persisting symptoms and QoL (WHO-5, EORTC QLQ-C30). RESULTS: Of 325 treated patients, 55 (17 %) survived after a median follow-up of 9.1 years. At treatment start, survivors had a median age of 60 years; 60 % were male; 40 % BRAF-mutated; 66 % stage M1c/d. Overall response rate was 89 %, including 69 % complete responses. Progression occurred in 22 (40 %). As of May 2024, 46 (84 %) were disease-free, 7 (13 %) had controlled disease, and 2 (4 %) progressed. IrAEs occurred in 39 (71 %), with 15 (27 %) grade 3/4. Persisting symptoms were reported by 19 (35 %), mainly endocrine insufficiencies, vitiligo, and fatigue. Median WHO-5 score was 76 %, and mean QLQ-C30 global health 70.1. Survivors with prior irAEs had significantly lower QoL (WHO-5, p = 0.026) and social functioning (QLQ-C30, p = 0.046). Of 21 survivors < 65 years (38 %), 11 (20 %) were employed at follow-up. CONCLUSION: Pembrolizumab induced long-term survival in a real-world pretreated melanoma cohort. Despite persisting symptoms in one third, QoL, when measured by standard instruments, was good for most survivors nearly a decade after treatment.
引用
- Dugas-Breit S, Forschner A, Erdmann M, et al. Characteristics and quality of life of nine-year survivors with metastatic melanoma treated with pembrolizumab beyond second-line therapy. Eur J Cancer. 2025. PMID: 41385939. doi:10.1016/j.ejca.2025.116149
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。